ImageneBio, Inc.
Business
ImageneBio is a clinical-stage biopharmaceutical company developing therapeutics for immunological, autoimmune and inflammatory diseases. Its lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody in Phase 2b development for atopic dermatitis with potential expansion into alopecia areata, asthma, rheumatoid arthritis and other indications. The company is advancing clinical trials in North America, with Phase 2b topline data anticipated in 2027. IMG-007 has demonstrated favorable safety and clinical activity in early-stage trials.
Summary from 10-K filed 2026-03-10
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| License revenue | 800,000 | 4 | 9 | 16 | 31 | |
| Research and development | 29 | 32 | 60 | 64 | 47 | |
| General and administrative | 21 | 8 | 25 | 22 | 18 | |
| Total operating expenses | 49 | 41 | 85 | 87 | 65 | |
| Loss from operations | −48 | −37 | −75 | −71 | −34 | |
| Interest income (expense), net | 2 | 374,000 | — | — | — | |
| Other income (expense), net | 717,000 | 71,000 | −22,000 | 2 | 23,000 | |
| Total other income, net | 3 | 445,000 | 7 | — | — | |
| Loss before income taxes | −46 | −37 | −68 | −69 | — | |
| Income tax benefit (provision) | 350,000 | −13,000 | 162,000 | — | — | |
| Net loss | −45 | −37 | −68 | −69 | −34 | |
| Accretion of redeemable convertible preferred shares | 7 | 12 | — | — | — | |
| Net Income (Loss) Available to Common Stockholders, Basic, Total | −52 | −48 | — | — | — | |
| Net loss per share, basic | −9.64 | −22.1 | −1.63 | −1.9 | −1.22 | |
| Net loss per share, diluted | −9.64 | −22.1 | −1.63 | −1.9 | −1.22 | |
| Weighted-average common shares outstanding, basic | 5 | 1 | 42 | 36 | 28 | |
| Unrealized gain on marketable securities | 87,000 | 116,000 | 715,000 | −763,000 | — | |
| Foreign currency translation adjustment | −29,000 | −38,000 | — | — | — | |
| Total comprehensive loss | −45 | −37 | −67 | −70 | −34 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 95 | 12 | 120 | 60 | 232 | |
| Marketable securities | 41 | 0 | 56 | 97 | — | |
| Prepaid expenses and other current assets | 5 | 350,000 | 3 | 3 | 4 | |
| Total current assets | 140 | 12 | 179 | 160 | 237 | |
| Operating lease right-of-use assets, net | 790,000 | 547,000 | 6 | 5 | 7 | |
| Other non-current assets | 5 | 1 | — | — | — | |
| Deferred offering costs | 0 | 2 | — | — | — | |
| Total assets | 153 | 16 | 192 | 172 | 248 | |
| Accounts payable | 1 | 5 | 2 | 2 | 2 | |
| Accrued expenses and other current liabilities | 8 | 3 | 9 | — | — | |
| Deferred revenue, current | 0 | 650,000 | — | — | — | |
| Lease liabilities, current | 2 | 309,000 | 4 | 2 | 2 | |
| Term loan | 0 | 8 | — | — | — | |
| Total current liabilities | 11 | 17 | 14 | 22 | 27 | |
| Lease liabilities, non-current | 713,000 | 239,000 | 7 | 4 | 5 | |
| Other non-current liabilities | 870,000 | 0 | — | — | — | |
| Total liabilities | 20 | 17 | 22 | 25 | 40 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Redeemable convertible preferred shares - $0.00005 par value; no shares and 2,905,696 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares and 2,163,434 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $0 and $163,575 as of December 31, 2025 and December 31, 2024, respectively | — | 159 | — | — | — | |
| Total redeemable convertible preferred shares | — | 159 | — | — | — | |
| Preferred stock value | — | — | — | — | — | |
| Additional paid-in capital | 363 | 2 | 452 | 362 | 353 | |
| Accumulated deficit | −230 | −180 | −282 | −214 | −145 | |
| Accumulated other comprehensive income (loss) | 87,000 | −2 | −48,000 | −763,000 | — | |
| Total stockholders' equity (deficit) | 133 | −161 | −126 | 147 | 208 | |
| Total liabilities, redeemable convertible preferred shares and stockholders' equity (deficit) | 153 | 16 | 192 | 172 | 248 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −45 | −37 | −68 | −69 | −34 | |
| Depreciation and amortization | 399,000 | 1 | — | — | — | |
| Non-cash interest expense | 489,000 | 0 | — | — | — | |
| Stock-based compensation expense | 15 | 0 | 8 | 8 | 5 | |
| Accretion/amortization of premium/discount of available-for-sale securities | −71,000 | 0 | −2 | — | — | |
| Amortization of right of use-assets | 634,000 | 389,000 | — | — | — | |
| Gain on early extinguishment of lease liability | −149,000 | 0 | — | — | — | |
| Loss on disposal of property and equipment | 0 | 1 | 5,000 | — | — | |
| Non-cash research and development expenses for the common stock issuable pursuant to Hutchmed Agreement | 0 | 14 | — | — | — | |
| Prepaid expenses and other current assets | −4 | −77,000 | 2 | 1 | −1 | |
| Other non-current assets | −1 | 54,000 | — | — | — | |
| Accounts payable | −3 | −523,000 | −3 | −291,000 | 361,000 | |
| Accrued expenses and other current liabilities | −9 | −1 | −8 | — | — | |
| Deferred revenue | −650,000 | 510,000 | −9 | −16 | −31 | |
| Operating lease liabilities | −1 | −425,000 | −2 | — | — | |
| Other long-term liabilities | −221,000 | 0 | 97,000 | — | — | |
| Net cash used in operating activities | −48 | −21 | −80 | −74 | −60 | |
| Cash divested in Non-OX40 divestiture | −5 | 0 | — | — | — | |
| Proceeds from disposal of property and equipment | 0 | 972,000 | — | — | — | |
| Purchases of marketable securities | −10 | 0 | −90 | −216 | — | |
| Maturities and sales of marketable securities | 10 | 10 | 155 | 118 | — | |
| Net cash (used in) provided by investing activities | −6 | 11 | 64 | −99 | −2 | |
| Proceeds from term loan | 15 | 8 | — | — | — | |
| Proceeds from exercise of stock options | 45,000 | 0 | 136,000 | 1 | 582,000 | |
| Issuance costs in connection with reverse recapitalization | −5 | −594,000 | — | — | — | |
| Cash acquired in connection with reverse recapitalization | 55 | 0 | — | — | — | |
| Proceeds from common stock issued in PIPE Financing, net of issuance costs | 71 | 0 | — | — | — | |
| Net cash provided by financing activities | 135 | 7 | 76 | 1 | 132 | |
| Effects of exchange rates on cash and cash equivalents | 604,000 | 87,000 | — | — | — | |
| Net increase (decrease) in cash and cash equivalents | 82 | −3 | — | — | — | |
| Cash paid for income taxes, net | 23,000 | 221,000 | — | — | — | |
| Accretion of redeemable convertible preferred shares | 7 | 12 | — | — | — | |
| Deferred offering costs in accrued expenses and other current liabilities | 0 | 1 | — | — | — | |
| Exchange of preferred shares into common stock upon closing of reverse recapitalization | 185 | 0 | — | — | — | |
| Forgiveness of term loan upon closing of reverse recapitalization | 23 | 0 | — | — | — | |
| Reverse recapitalization issuance costs in accrued expenses | 3 | 0 | — | — | — | |
| Issuance of promissory note in connection with divesture | 7 | 0 | — | — | — | |
| Net assets derecognized in connection with Non-OX40 Divestiture | 5 | 0 | — | — | — | |
| Right-of-use assets acquired by assuming operating lease liability | 74,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ImageneBio, Inc.'s CIK number?
ImageneBio, Inc.'s SEC CIK number is 0001835579 (1835579). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ImageneBio, Inc.'s SEC filings?
All of ImageneBio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ImageneBio, Inc. last report earnings?
ImageneBio, Inc. (IMA) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211935). This is ImageneBio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ImageneBio, Inc.'s most recent earnings 8-K?
ImageneBio, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211935. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ImageneBio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →